第8届逆转录病毒和机会性感染会议(2001-2)

 

8th Conference on Retroviruses and Opportunistic Infections
第8届逆转录病毒和机会性感染会议(2001-2)

A Call to Action: Opening Session Highlights Impact of HIV in Underdeveloped Countries
行动起来：会议突出HIV对发展中国家的影响

Viral Reservoirs and the Persistence of HIV-1
病毒贮池和HIV-1持续

Protease Inhibitor Substitution: Further Evidence of Success With Improved Medication Adherence
蛋白酶抑制剂替代：成功地改善药物治疗的证据

NRTI Sequencing and Phosphorylation: Setting the Record Straight
NRTI序列和磷酸化：直接记录

P-Glycoprotein and the Cellular Efflux Pumps: Not Just for the Pharmacologists Anymore
P-糖蛋白和细胞外流泵：不再仅仅为了药理学家

The Chiron Vaccine Program: Progress, Promise and Limitations
Chiron 疫苗计划：进展、成果和限制

Therapeutic HIV Vaccines Make a Comeback
治疗性HIV疫苗

Does HCV Accelerate HIV Disease Progression?
丙型肝炎病毒加速HIV疾病恶化吗？

Coadministration of Rifampin and Efavirenz, and Other Clinical Pearls
联合应用利福平，Efavirenz以及其它临床治疗

Structured Treatment Interruption (STI) ?Not Ready for Clinical Prime Time
构建治疗中断（STI）? 还未为临床黄金时段准备好

What Resistance Pattern in Likely in Patients Failing Lopinavir/Ritonavir?
Lopinavir/Ritonavir失败的病人抵抗类型如何？

Reassuring Durability of First-Line Efavirenz-Based Therapy
第一线Efavirenz为基础的治疗的可靠持久性

Clinical and Immunologic Outcomes in Patients on Virologically Failing Regimens
病毒学失败方案病人的临床和免疫学结果

The Continued Promise of Once-Daily Regimens of RT Inhibitors
反转录酶抑制剂每日一次方案的结果

Is Treatment Intensification Advisable for Patients With Transient Viral "Blips"?
有短暂病毒"信号"的病人强化治疗可取吗？

Studies Confirm the Immunologic Benefit of Interleukin-2
研究确定了白介素-2的免疫学益处

Positive Results Seen From Treatment of Primary HIV Infection
原发HIV感染治疗的阳性结果

Host-Directed Enhancement of Antiretroviral Drug Effects
抗逆转录病毒药物效应的宿主指导性增强

Retrospective Comparison of Outcomes With Nevirapine- or Efavirenz-Based Regimens
Nevirapine或Efavirenz为基础的方案治疗作用的回顾性比较

Promising Early Steps With Gene Therapy for HIV
基因治疗HIV的颇有前景的早期步骤

Update on Postexposure Prophylaxis After Sexual HIV Risk
性传播HIV风险后的暴露后预防

Estimating the Risk of Sexual HIV Transmission: Implications for the African Epidemic
性传播HIV风险估计：非洲人传染病的含义

Sexual Transmission From Patients With Primary HIV Infection May Precede Retroviral Symptoms
原发HIV感染病人的性传播可先于逆转录病毒的症状 Increasing High-Risk Behavior: It's Not Just Gay Men
增加高风险行为：不仅仅是男性同性恋者

Pediatric Antiretroviral Therapy: Should We Still Hit Early, Hit Hard?
儿科抗逆转录病毒治疗：仍需早期和强力进行吗？

Where Does HIV Hide? Latent Infection and Cellular Reservoirs in Children
HIV藏在那里？儿童的潜在性感染和细胞贮池

A Tale of Two Worlds: Stopping Global Mother-to-Child HIV Transmission
两个世界的故事：终止全球性母婴HIV传播

Peripheral Neuropathy: A Universal Phenomenon in HIV Patients?
外周神经病：HIV病人的普遍现象？

Mucosal Immunity: Neglected but Essential to HIV Vaccine Research
黏膜免疫：被忽视的但对HIV疫苗研究是必要的

An Alternative Way to Build Immune Responses to an HIV Vaccine
对HIV疫苗建立免疫应答的选择性方法

Lipodystrophy ?What Does the MACS Show Us?
脂质营养不良？MACS给我们显示了什么？

Viral "Blips": Benign or Portent of Bad Things to Come?
病毒"信号"：坏事情到来的征兆？

Are HIV-Specific Immune Responses Responsible for Controlling Transient Viral "Blips"
HIV特异性免疫应答负责控制短暂病毒"信号"吗？

Clinical Significance of Transmitted Drug-Resistant HIV-1
传播的抗药性HIV-1的临床意义

Decreased Bone Mineral Density: Many Questions, Few Answers
骨矿物质密度减少：问题多，答案少

Nevirapine for Prevention of Mother-to-Child HIV Transmission: Concerns over Resistance
Nevirapine预防HIV母婴传播：抗药问题

How to Manage Lactic Acidemia in HIV-Infected Patients?
如何处理HIV感染病人的乳酸血症？

New Antiretrovirals for Children: What Looks Promising in the Pediatric Pipeline?
用于儿童的新的抗逆转录病毒治疗：哪种方法更有前景？

How Low Can You Go? Predictive Value of Pretreatment CD4+ Cell Count and Viral Load
治疗前CD4+细胞计数和病毒负荷的预报值

A Smaller, Simpler Amprenavir
一种小的、简单的Amprenavir

Once- or Twice-Daily Amprenavir/Ritonavir Regimens
每日一次或两次Amprenavir/Ritonavir方案

Project SAFE: The CDC's New and Improved Prevention Strategy
SAFE计划：CDC新的和改良的预防方案

Matters of Fate: Is Pediatric Disease Progression Determined Prior to Birth?
儿童疾病恶化在出生前就决定了吗？

Maximal Viral Suppression Takes Time: Insights From Lopinavir/Ritonavir Vs Nelfinavir
最大病毒抑制时间：比较Amprenavir/Ritonavir和Nelfinavir?

DOT for HIV: An Idea Whose Time Has Come?
对HIV直接观察治疗（DOT）

Translating Science Into Practice: The Impact of New Recommendations for Prevention of Mother-to-Child HIV Transmission
母婴HIV传播预防的新建议的影响

SCH C: Early Evaluation of a CCR5 Antagonist
SCH C:一种CCR5拮抗剂的早期评价

Circumcision as an HIV Prevention Intervention
包皮环切术作为HIV预防干预

Reduced Fitness of Protease Inhibitor-Resistant HIV In Vivo
体内HIV蛋白酶抑制剂抵抗

What Role for Nevirapine in Preventing Perinatal Transmission: Results of PACTG 316
Nevirapine在预防围产期传播中的作用

Further Fuel to the "When-to-Start" Controversy
有关治疗时机的争论

T-20 and 5-Helix: Novel HIV Entry Inhibitors
T-20和5-螺旋：新的HIV进入抑制剂

Issues in Pediatric Therapy: Toxicity, Pharmacokinetics, and Resistance
儿科治疗问题：毒性、药代动力学和抗药